Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 199

1.

KIBRA regulates Hippo signaling activity via interactions with large tumor suppressor kinases.

Xiao L, Chen Y, Ji M, Dong J.

J Biol Chem. 2011 Mar 11;286(10):7788-96. doi: 10.1074/jbc.M110.173468. Epub 2011 Jan 13.

2.

KIBRA regulates aurora kinase activity and is required for precise chromosome alignment during mitosis.

Zhang L, Iyer J, Chowdhury A, Ji M, Xiao L, Yang S, Chen Y, Tsai MY, Dong J.

J Biol Chem. 2012 Oct 5;287(41):34069-77. doi: 10.1074/jbc.M112.385518. Epub 2012 Aug 17.

3.

Mst2 and Lats kinases regulate apoptotic function of Yes kinase-associated protein (YAP).

Oka T, Mazack V, Sudol M.

J Biol Chem. 2008 Oct 10;283(41):27534-46. doi: 10.1074/jbc.M804380200. Epub 2008 Jul 17.

4.

Tumor suppressor LATS1 is a negative regulator of oncogene YAP.

Hao Y, Chun A, Cheung K, Rashidi B, Yang X.

J Biol Chem. 2008 Feb 29;283(9):5496-509. Epub 2007 Dec 24.

5.

Serum deprivation inhibits the transcriptional co-activator YAP and cell growth via phosphorylation of the 130-kDa isoform of Angiomotin by the LATS1/2 protein kinases.

Adler JJ, Johnson DE, Heller BL, Bringman LR, Ranahan WP, Conwell MD, Sun Y, Hudmon A, Wells CD.

Proc Natl Acad Sci U S A. 2013 Oct 22;110(43):17368-73. doi: 10.1073/pnas.1308236110. Epub 2013 Oct 7.

6.

Deubiquitinating Enzyme USP9X Suppresses Tumor Growth via LATS Kinase and Core Components of the Hippo Pathway.

Toloczko A, Guo F, Yuen HF, Wen Q, Wood SA, Ong YS, Chan PY, Shaik AA, Gunaratne J, Dunne MJ, Hong W, Chan SW.

Cancer Res. 2017 Sep 15;77(18):4921-4933. doi: 10.1158/0008-5472.CAN-16-3413. Epub 2017 Jul 18.

PMID:
28720576
7.

Evolutionary and molecular facts link the WWC protein family to Hippo signaling.

Wennmann DO, Schmitz J, Wehr MC, Krahn MP, Koschmal N, Gromnitza S, Schulze U, Weide T, Chekuri A, Skryabin BV, Gerke V, Pavenstädt H, Duning K, Kremerskothen J.

Mol Biol Evol. 2014 Jul;31(7):1710-23. doi: 10.1093/molbev/msu115. Epub 2014 Mar 27.

PMID:
24682284
8.

KIBRA protein phosphorylation is regulated by mitotic kinase aurora and protein phosphatase 1.

Xiao L, Chen Y, Ji M, Volle DJ, Lewis RE, Tsai MY, Dong J.

J Biol Chem. 2011 Oct 21;286(42):36304-15. doi: 10.1074/jbc.M111.246850. Epub 2011 Aug 30.

9.

Angiomotin family proteins are novel activators of the LATS2 kinase tumor suppressor.

Paramasivam M, Sarkeshik A, Yates JR 3rd, Fernandes MJ, McCollum D.

Mol Biol Cell. 2011 Oct;22(19):3725-33. doi: 10.1091/mbc.E11-04-0300. Epub 2011 Aug 10.

10.

Role of Angiomotin-like 2 mono-ubiquitination on YAP inhibition.

Kim M, Kim M, Park SJ, Lee C, Lim DS.

EMBO Rep. 2016 Jan;17(1):64-78. doi: 10.15252/embr.201540809. Epub 2015 Nov 23.

11.

Upregulation of miR-181c contributes to chemoresistance in pancreatic cancer by inactivating the Hippo signaling pathway.

Chen M, Wang M, Xu S, Guo X, Jiang J.

Oncotarget. 2015 Dec 29;6(42):44466-79. doi: 10.18632/oncotarget.6298.

12.

KIBRA exhibits MST-independent functional regulation of the Hippo signaling pathway in mammals.

Moleirinho S, Chang N, Sims AH, Tilston-Lünel AM, Angus L, Steele A, Boswell V, Barnett SC, Ormandy C, Faratian D, Gunn-Moore FJ, Reynolds PA.

Oncogene. 2013 Apr 4;32(14):1821-30. doi: 10.1038/onc.2012.196. Epub 2012 May 21.

PMID:
22614006
13.

Kibra is a regulator of the Salvador/Warts/Hippo signaling network.

Genevet A, Wehr MC, Brain R, Thompson BJ, Tapon N.

Dev Cell. 2010 Feb 16;18(2):300-8. doi: 10.1016/j.devcel.2009.12.011.

14.

The characterisation of LATS2 kinase regulation in Hippo-YAP signalling.

Hoa L, Kulaberoglu Y, Gundogdu R, Cook D, Mavis M, Gomez M, Gomez V, Hergovich A.

Cell Signal. 2016 May;28(5):488-497. doi: 10.1016/j.cellsig.2016.02.012. Epub 2016 Feb 18.

PMID:
26898830
15.

Ski regulates Hippo and TAZ signaling to suppress breast cancer progression.

Rashidian J, Le Scolan E, Ji X, Zhu Q, Mulvihill MM, Nomura D, Luo K.

Sci Signal. 2015 Feb 10;8(363):ra14. doi: 10.1126/scisignal.2005735.

16.

A YAP/TAZ-induced feedback mechanism regulates Hippo pathway homeostasis.

Moroishi T, Park HW, Qin B, Chen Q, Meng Z, Plouffe SW, Taniguchi K, Yu FX, Karin M, Pan D, Guan KL.

Genes Dev. 2015 Jun 15;29(12):1271-84. doi: 10.1101/gad.262816.115.

17.

Statin suppresses Hippo pathway-inactivated malignant mesothelioma cells and blocks the YAP/CD44 growth stimulatory axis.

Tanaka K, Osada H, Murakami-Tonami Y, Horio Y, Hida T, Sekido Y.

Cancer Lett. 2017 Jan 28;385:215-224. doi: 10.1016/j.canlet.2016.10.020. Epub 2016 Oct 20.

PMID:
27773750
18.

Sphingosylphosphorylcholine regulates the Hippo signaling pathway in a dual manner.

Kemppainen K, Wentus N, Lassila T, Laiho A, Törnquist K.

Cell Signal. 2016 Dec;28(12):1894-1903. doi: 10.1016/j.cellsig.2016.09.004. Epub 2016 Sep 12.

PMID:
27634386
19.

The Hippo pathway is controlled by Angiotensin II signaling and its reactivation induces apoptosis in podocytes.

Wennmann DO, Vollenbröker B, Eckart AK, Bonse J, Erdmann F, Wolters DA, Schenk LK, Schulze U, Kremerskothen J, Weide T, Pavenstädt H.

Cell Death Dis. 2014 Nov 13;5:e1519. doi: 10.1038/cddis.2014.476.

20.

RAC-LATS1/2 signaling regulates YAP activity by switching between the YAP-binding partners TEAD4 and RUNX3.

Jang JW, Kim MK, Lee YS, Lee JW, Kim DM, Song SH, Lee JY, Choi BY, Min B, Chi XZ, Bae SC.

Oncogene. 2017 Feb 16;36(7):999-1011. doi: 10.1038/onc.2016.266. Epub 2016 Jul 18.

PMID:
27425596

Supplemental Content

Support Center